CURN.SW stock falls 6.92% to CHF24.20 intraday 13 Mar 2026: watch clinical catalysts

CURN.SW stock opened at CHF23.40 and is trading at CHF24.20 on the SIX exchange intraday on 13 Mar 2026, down 6.92% from the previous close of CHF26.00. Volume is light at 1,871 shares versus an average of 4,804, but relative volume is elevated at 2.34x, signaling outsized intraday moves. The Healthcare sector is down 1.16% today, but Curatis Holding AG is underperforming peers as traders react to valuation and trial-risk concerns. We break down the drivers, financials, technicals, and Meyka AI’s forecast for near-term price action.

Intraday price action and quick facts on CURN.SW stock

Curatis Holding AG (CURN.SW) trades on SIX in Switzerland. The stock hit a day high of CHF24.20 and day low of CHF22.80 today. Market cap stands at CHF119,947,771.00 and shares outstanding are 5,147,973. Year range is CHF9.14 to CHF27.90, with the 50-day average at CHF16.65 and 200-day average at CHF13.27. Current EPS is -0.84 with a reported PE of -27.74, reflecting negative earnings.

Why CURN.SW stock is a top loser intraday

Selling pressure appears tied to clinical and valuation risk. Curatis runs multiple early- and mid-stage programs. Trial-readout uncertainty raises short-term volatility for a small-cap biotech. Relative to the Healthcare sector decline of 1.16% today, CURN.SW stock’s -6.92% move signals stock-specific risk. Lower liquidity amplifies swings: average volume is 4,804 shares and today’s volume is 1,871, but buyers and sellers show wider spreads in small-cap biotechs.

Fundamentals and valuation: CURN.SW analysis

Curatis reports revenue per share TTM of 2.37 and shareholders’ equity per share of 15.67. Price-to-book is about 1.49 and price-to-sales is 17.02, indicating high valuation against modest revenue. Operating margins and free cash flow are negative: operating cash flow per share TTM is -0.28. Current ratio is 1.81, and cash per share is 1.04 CHF. These metrics show modest liquidity but negative profitability, typical for development-stage drug makers.

Technical snapshot and trading signals for CURN.SW stock

Momentum is strong but overbought in the short run. RSI sits at 66.46 and CCI reads 223.35, signaling overbought conditions. MACD is positive with MACD 1.14 and signal 0.57, while ADX at 30.73 signals a strong trend. Bollinger middle band is CHF18.56 and upper band CHF22.81. Short-term support now sits near CHF22.80 and immediate resistance near the intraday high CHF24.20.

Analyst grade, risks and opportunities in CURN.SW stock

Meyka AI rates CURN.SW with a score out of 100: 63.33/100 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Key risks include clinical trial failure, small-cap liquidity, and negative operating margins. Opportunities include upside from positive Phase II data and pipeline partnerships. These grades are not guaranteed and are not financial advice.

News flow, catalysts and what traders should watch

Watch clinical readouts for C-PTBE-01 (Phase IIb) and C-AM-01 (Phase IIa). Corporate announcements, licensing deals, or unexpected financing needs would move the stock. Curatis’ website posts filings and updates; see the company site for press releases. Also monitor sector moves: large-cap healthcare leaders can shift investor flows into or out of small-cap biotechs on risk-on days. Curatis website and the company profile image provide company reference material.

Final Thoughts

CURN.SW stock finished the intraday move at CHF24.20, down 6.92% on 13 Mar 2026 as traders reacted to pipeline and valuation risk. The company shows a mixed balance sheet with CHF1.04 cash per share and book value per share of CHF15.67, but negative EPS of -0.84 and weak operating cash flow. Technicals point to short-term strength but overbought readings increase the chance of a pullback toward support at CHF22.80. Meyka AI’s forecast model projects a monthly level of CHF18.59, implying an estimated downside of -23.18% versus the current price of CHF24.20; forecasts are model-based projections and not guarantees. For traders, key triggers remain Phase II readouts and any financing or licensing updates. We suggest close monitoring of volume and trial news before adjusting positions. Meyka AI, an AI-powered market analysis platform, will update the forecast if new material arrives.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.